Business Context and Reporting Period
Shuttle Pharmaceuticals Holdings, Inc. (SHPH), a Delaware corporation and emerging growth company, filed this Form 8-K on October 31, 2024, to report the consummation of a public offering that closed on the same date. The company is focused on developing product candidates, including the radiation sensitizer Ropidoxuridine.
Key Financial Metrics and Capital Structure
- Gross Proceeds: Approximately $4.5 million raised from the offering.
- Securities Issued:
- 395,574 shares of Common Stock.
- 2,555,246 Pre-Funded Warrants (exercisable at $0.001 per share).
- 2,950,820 Common Warrants (exercisable at $1.40 per share, expiring in five years).
- Offering Price: $1.525 per unit (Common Stock + Common Warrant) and $1.524 per unit (Pre-Funded Warrant + Common Warrant).
- Outstanding Shares: 3,341,673 shares of Common Stock outstanding immediately following the closing (excluding warrant exercises).
- Transaction Costs: Placement agent fees totaled 9.0% of gross proceeds. The company also agreed to reimburse legal expenses up to $100,000 and non-accountable fees up to $50,000.
Material Changes and Use of Proceeds
The primary material change is the increase in equity capital and the issuance of new warrants. The company intends to use the net proceeds primarily to fund IND-enabling and Phase I and II clinical trials. Specifically, $2.3 million of the proceeds are designated for payments owed to Theradex Systems, Inc., the clinical research organization supporting the Phase II trials for Ropidoxuridine.
Guidance, Outlook, and Restrictions
- Lock-Up Agreements: Executive officers, directors, and stockholders owning 5% or more of the company's stock are subject to a 60-day lock-up period from the closing date.
- Issuance Restrictions: The company agreed not to issue Common Stock or equivalents for 60 days and is restricted from Variable Rate Transactions for 120 days post-closing.
- Warrant Exercise Limits: Holders are restricted from exercising warrants if it would result in beneficial ownership exceeding 4.99% (or 9.99% with notice) of outstanding shares.
- Outlook: Management's focus remains on advancing clinical trials for its product pipeline using the newly raised capital.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the 9.0% placement fee and reimbursable expenses.
- Confirm the current cash balance and runway extension provided by the $4.5 million gross proceeds.
- Review the specific terms of the Pre-Funded Warrants and Common Warrants in Exhibits 4.1 and 4.2.
- Monitor the status of the $2.3 million payment obligation to Theradex Systems, Inc.
- Check for any subsequent filings regarding the exercise of warrants or changes in the 60-day lock-up period.